As gene therapies continue to advance, AAV manufacturing has become one of the biggest challenges to successful commercialization. This article explores how biotech companies can reduce development and manufacturing risks by partnering with an end-to-end CDMO that combines scalable processes, Quality by Design (QbD) principles, advanced analytics, and integrated manufacturing capabilities. Discover how 3PBIOVIAN’s AAVion®…
Adenovirus vectors are critical for gene therapy and vaccine applications, yet their GMP production using adherent cell systems poses unique challenges during scale-up. In this work, 3PBIOVIAN, in collaboration with Cytiva, developed an end-to-end process development strategy for adherent adenovirus production using the iCELLis bioreactor technology. After first establishing…
Please fill in the form for access to the download.
"*" indicates required fields
Latest updates
The European CMO Model, Powering Biologics Innovation
From Concept To Commercial Reality: Successful Upscaling Strategies For Viral Vector Manufacturing
Process development, scale-up and challenges of TM adenovirus GMP process in the iCELLis
Myths That Make Early CDMO Engagement Look Like A Risk
De-Risking AAV Production By Working With An End-To-End CDMO